JPMorgan analyst Jessica Fye reinstates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Overweight rating and a price target of $420.00.

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $294.30 yesterday.